GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomarin Pharmaceutical Inc (FRA:BM8) » Definitions » Inventories, Other

Biomarin Pharmaceutical (FRA:BM8) Inventories, Other : €1,047 Mil (As of Mar. 2024)


View and export this data going back to 1999. Start your Free Trial

What is Biomarin Pharmaceutical Inventories, Other?

Other inventories including goods for resale, stocks in transit, consignment stocks, etc. Biomarin Pharmaceutical's other inventories for the quarter that ended in Mar. 2024 was €1,047 Mil.

Biomarin Pharmaceutical's quarterly other inventories increased from Sep. 2023 (€-0 Mil) to Dec. 2023 (€0 Mil) and increased from Dec. 2023 (€0 Mil) to Mar. 2024 (€1,047 Mil).


Biomarin Pharmaceutical Inventories, Other Historical Data

The historical data trend for Biomarin Pharmaceutical's Inventories, Other can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomarin Pharmaceutical Inventories, Other Chart

Biomarin Pharmaceutical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Inventories, Other
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Biomarin Pharmaceutical Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Inventories, Other Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 1,046.94

Biomarin Pharmaceutical Inventories, Other Calculation

Other inventories including goods for resale, stocks in transit, consignment stocks, etc.


Biomarin Pharmaceutical (FRA:BM8) Business Description

Traded in Other Exchanges
Address
770 Lindaro Street, San Rafael, CA, USA, 94901
BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the U.S. in 2023.

Biomarin Pharmaceutical (FRA:BM8) Headlines

No Headlines